title: Financial incentives in cancer care and impact on prescribing practice.
authors.forename: Hui-Li
authors.initials: HL
authors.lastname: Wong
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Field
authors.forename: Jeremy D
authors.initials: JD
authors.lastname: Shapiro
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: McKendrick
authors.forename: Peter
authors.initials: P
authors.lastname: Gibbs
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics*; D001315:Australia; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D011307:Drug Prescriptions / Q000191:economics; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D016304:Hospitals, Private / Q000191:economics; D006779:Hospitals, Public / Q000191:economics; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil